BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group)

N/A

Report date: 2024/11/22 20:00:28

Base Information

Drug NameBCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group)
Drug Alias NameBCMA CAR-NK 92 cells - Asclepius Technology CompanyAdoptive BCMA CAR-NK Cells therapy - Asclepius Technology Company Group
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy > Chimeric antigen receptor NK-92 cell therapy
Mechanisms of ActionNatural killer cell replacementsB-cell maturation protein modulators
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesAsclepius Technology Company Group
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAsclepius Technology Company Group
Active IndicationsN/A
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A